MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$93K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of marketab...
Asset impairment
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable
Lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-14,892
-9,796
-9,436
-8,624
Depreciation and amortization
272
283
365
533
Amortization of premiums and discounts on marketable securities
41
59
49
46
Stock-based compensation
304
344
435
600
Noncash operating lease expense
161
154
151
148
Asset impairment
5,077
-
-
-
Prepaid expenses and other assets
-195
308
-1,623
-1,195
Accounts payable
-492
1,059
-380
-153
Accrued liabilities and other liabilities
-13
4,735
49
-367
Lease liabilities
-276
-269
-263
-254
Other long-term liabilities
-36
-36
-35
-34
Net cash used in operating activities
-9,715
-13,363
-7,638
-6,268
Sales and maturities of marketable securities
9,786
1,300
6,003
8,700
Purchases of marketable securities
-
-
0
0
Net cash provided by investing activities
9,786
1,300
6,003
8,700
Net proceeds from at-the-market sales
0
1,234
-
-
Proceeds from issuance of common stock
-
-
20,276
2,000
Proceeds from exercise of stock options
0
14
-
-
Proceeds from shares issued under espp
22
-
17
0
Net cash provided by financing activities
22
1,248
20,293
0
Net increase (decrease) in cash and cash equivalents
93
-10,815
18,658
2,432
Cash and cash equivalents - beginning of period
15,167
25,982
7,324
27,727
Cash and cash equivalents - end of period
15,260
15,167
25,982
7,324
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of marketable...
$9,786K
(-73.94%↓ Y/Y)
Proceeds from shares
issued under espp
$22K
(15.79%↑ Y/Y)
Net cash provided by
investing activities
$9,786K
(-9.83%↓ Y/Y)
Net cash provided by
financing activities
$22K
(-98.91%↓ Y/Y)
Net increase
(decrease) in cash and cash...
$93K
(100.41%↑ Y/Y)
Canceled cashflow
$9,715K
Asset impairment
$5,077K
Stock-based compensation
$304K
(-84.42%↓ Y/Y)
Depreciation and
amortization
$272K
(-78.87%↓ Y/Y)
Prepaid expenses and
other assets
-$195K
(-111.36%↓ Y/Y)
Noncash operating lease
expense
$161K
(-44.10%↓ Y/Y)
Accrued liabilities and
other liabilities
-$13K
(99.68%↑ Y/Y)
Net cash used in
operating activities
-$9,715K
(72.79%↑ Y/Y)
Canceled cashflow
$6,022K
Net loss
-$14,892K
(60.59%↑ Y/Y)
Accounts payable
-$492K
(82.48%↑ Y/Y)
Lease liabilities
-$276K
(43.44%↑ Y/Y)
Amortization of premiums and
discounts on marketable...
$41K
(-89.38%↓ Y/Y)
Other long-term
liabilities
-$36K
(45.45%↑ Y/Y)
Buy us a coffee
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)